SCHEMBL6156652

SCHEMBL6156652

Cc1cc(NC(=O)NN(c2ccccc2)c2cccc(CN)c2)ccc1N1CCCCC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.38
LMNA P02545 3/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 1/20 0.38
TPSAB1 Q15661 2/20 0.36
TPSD1 Q9BZJ3 2/20 0.36
TPSG1 Q9NRR2 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36
CCKBR P32239 1/20 0.36
POLB P06746 1/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
TP53 P04637 2/20 0.35
CDK2 P24941 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP2D6 P10635 1/20 0.35
OPRM1 P35372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158842 0.97 KMT2A (0.38) F10LMNATSHRHPGDKMT2A
SCHEMBL6159444 0.94 F10 (0.37) F10LMNATSHRHPGDKMT2A
SCHEMBL6156018 0.88 S1PR1 (0.37) LMNATSHRHPGDTPSAB1TPSD1
SCHEMBL6157574 0.87 ALDH1A1 (0.41) LMNAHPGDKMT2AMAPTGAA
SCHEMBL6156115 0.87 TSHR (0.46) F10LMNATSHRHPGDKMT2A
SCHEMBL6157131 0.86 TSHR (0.46) F10LMNATSHRHPGDKMT2A
SCHEMBL6156656 0.86 F10 (0.47) F10TSHRHPGDKMT2AMAPT
SCHEMBL6157189 0.85 KCNJ6 (0.40) LMNATSHRHPGDKMT2AMAPT
SCHEMBL6156891 0.84 F10 (0.39) F10LMNATSHRHPGDKMT2A
SCHEMBL6157569 0.82 TP53 (0.38) F10LMNATSHRHPGDTPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US claimed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP claimed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP disclosed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 F10 6/4885LMNA 1705/4885TSHR 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.